Human growth hormone (HGH) can be injected intramuscularly, and for decades it routinely was. Clinical trials from the early era of growth hormone therapy compared the two routes head to head and found that intramuscular and subcutaneous injections produce similar growth outcomes and similar antibody responses. Despite that equivalence, subcutaneous injection became the dominant method by the mid-1980s for reasons that go beyond efficacy, and understanding why tells you a lot about what actually matters when choosing an injection route.
How Absorption Differs Between the Two Routes
The most striking difference between intramuscular and subcutaneous HGH injection is not how much hormone reaches your bloodstream but how fast it gets there. An intramuscular injection delivers a sharp spike: blood levels of growth hormone peak around two hours after the shot, reaching average concentrations roughly five times higher than a subcutaneous injection of the same dose. That steep peak drops quickly, and levels return to baseline within about eight to ten hours.1Pediatric Research. Absorption of human growth hormone injected subcutaneously and intramuscularly in growth deficient dwarfs
A subcutaneous injection, by contrast, creates a lower, broader curve. Blood levels peak later, around four hours, and the hormone lingers in circulation for roughly eighteen hours before returning to baseline. The total amount of growth hormone your body is exposed to over those hours ends up comparable between the two methods; the difference is in the shape of the curve, not the area under it.1Pediatric Research. Absorption of human growth hormone injected subcutaneously and intramuscularly in growth deficient dwarfs
This matters because the body’s natural secretion of growth hormone happens in pulses, not as a steady drip. Neither injection method perfectly mimics that pulsatile pattern, but the slower subcutaneous release may be somewhat closer to the natural rhythm than the sharp intramuscular spike. Clinicians eventually came to see the flatter profile as a minor advantage, though it is worth noting that clinical outcomes did not clearly separate the two approaches.
Growth Outcomes Are Essentially the Same
If you are considering HGH therapy for growth hormone deficiency, the practical question is whether one route makes you grow more. The answer, based on the head-to-head trials available, is no. In one trial that followed children with growth hormone deficiency through nine months of therapy, the height velocity and the change in height velocity at three-month intervals were similar whether the children received intramuscular or subcutaneous injections.2The Journal of Clinical Endocrinology & Metabolism. A Comparison of Subcutaneous and Intramuscular Administration of Human Growth Hormone in the Therapy of Growth Hormone Deficiency
Another trial measured IGF-I and IGF-II, the downstream growth factors that actually mediate most of growth hormone’s effects on bone and tissue. After four days of injections, IGF-I levels tripled and IGF-II levels nearly doubled in both groups, with no meaningful difference between the intramuscular and subcutaneous arms. After six months, growth rates remained statistically indistinguishable, and only two patients out of the entire cohort developed antibodies to the hormone.3PubMed. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response
A separate comparison confirmed the same pattern for antibody formation specifically: the immune response to growth hormone was similar regardless of injection route.4Pediatric Research. Comparison of intramuscular and subcutaneous injections of growth hormone This finding mattered because early growth hormone preparations derived from human pituitary glands sometimes triggered antibodies that blunted the hormone’s effectiveness. Knowing that neither route worsened this problem made the choice between them a matter of comfort rather than efficacy.
Why Subcutaneous Became the Standard
If the two routes produce the same growth and the same immune response, why did the medical world settle so firmly on subcutaneous injection? Patient comfort was the deciding factor. When researchers conducted a crossover study, letting the same patients try both methods over the course of therapy, the preference was lopsided. Patients overwhelmingly chose the subcutaneous route, reporting less pain and better tolerance.5PubMed. A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency In a separate trial, both the children receiving the injections and their parents independently preferred subcutaneous administration.6Pediatrics. Subcutaneous Versus Intramuscular Growth Hormone Therapy: Growth and Acute Somatomedin Response
That preference is not trivial. Growth hormone therapy for deficiency is typically a daily injection continued over years, often starting in childhood. A route that hurts more is a route that leads to more missed doses. The researchers studying these patients explicitly noted that subcutaneous delivery would reduce noncompliance, and for a treatment that depends on consistency, compliance is everything.5PubMed. A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency
The practical logistics helped too. Subcutaneous injections use shorter, thinner needles and can be self-administered with minimal training. Intramuscular injections typically require a longer needle and more anatomical precision, making them harder to do at home without assistance, especially for a child or a parent learning to give shots.
A Brief History of the Shift
Growth hormone therapy has been available since the late 1950s, when it was first used in children with severe deficiency. For its first few decades, the hormone was extracted from the pituitary glands of cadavers, making supply extremely limited.7PubMed Central. History of growth hormone therapy During that era, intramuscular injection was the norm. Doses were given two or three times a week rather than daily, partly because the limited supply did not allow for more frequent dosing and partly because the intramuscular route was what clinicians were accustomed to.
The introduction of recombinant human growth hormone in the mid-1980s changed the picture dramatically. With an unlimited supply of synthetic hormone, daily dosing became feasible, and the question of patient comfort for daily injections suddenly mattered much more than it had for twice-weekly shots. The comparison trials described above were conducted during this transitional period, and their results sealed subcutaneous injection as the new standard. By the 1990s, virtually every commercial HGH product was labeled for subcutaneous use, and the pen-style auto-injector devices that dominate the market today are all designed for subcutaneous delivery.
Risks Specific to Intramuscular Injection
Intramuscular injection in general carries risks that subcutaneous injection largely avoids. These risks are not unique to growth hormone; they apply to any medication given into muscle. But because growth hormone therapy involves hundreds or thousands of injections over a treatment course, even a small per-injection risk compounds over time.
The most serious concern is nerve injury. The gluteal region, the most common site for intramuscular injections, sits near the sciatic nerve. Accidental damage to that nerve can cause lasting neuropathic pain and weakness. One documented case involved a patient who developed chronic, intractable pain after a gluteal injection that injured the sciatic nerve, and the pain persisted even as motor weakness slowly recovered.8PubMed Central. Iatrogenic Injury to the Sciatic Nerve due to Intramuscular Injection: A Case Report This risk exists any time a needle goes into the gluteal muscle, not just with growth hormone, but it is a risk you can eliminate entirely by choosing subcutaneous injection instead.
Intramuscular hematomas are another hazard. If a needle punctures a blood vessel within the muscle, bleeding can accumulate and compress nearby nerves. In one reported case, an intramuscular injection in the gluteal area caused a hematoma that compressed the superior gluteal nerve, resulting in temporary muscle weakness that resolved only after the collected blood was aspirated.9PubMed Central. Intramuscular hematoma with motor weakness after trigger point injection
Proper technique reduces these risks but does not eliminate them. Needle length needs to be matched to the patient’s body composition. A systematic review of dorsogluteal injection depth found that women with a BMI of 25 or above need needles longer than 38 mm to reliably reach muscle tissue, while men generally need longer needles only at a BMI of 35 or above. When there is doubt about whether the needle will reach the muscle, ultrasound guidance is recommended.10PubMed. Dorsogluteal intramuscular injection depth needed to reach muscle tissue according to body mass index and gender: A systematic review All of this technical calibration is unnecessary with a subcutaneous injection, which only needs to reach the fat layer just below the skin.
Injection Site Problems with Subcutaneous HGH
Subcutaneous injection is not entirely free of local complications. The most well-documented issue is lipoatrophy, a localized loss of fat tissue at or near the injection site. Growth hormone has a direct lipolytic effect, meaning it breaks down fat. When the hormone sits in subcutaneous tissue long enough, it can dissolve the fat around the injection point, leaving visible dents or depressions in the skin.
This problem became especially apparent during trials of a long-acting pegylated growth hormone formulation. The trial protocol required injections in the same thigh to reduce variability, and five cases of lipoatrophy appeared, forcing a temporary halt. After an injection-site rotation plan was introduced, the trial resumed, but three more cases developed, including one in a child, and the study was ultimately terminated. Investigators concluded that the prolonged local presence of the hormone in the subcutaneous fat was the direct cause.11Endocrinology, Diabetes & Metabolism Case Reports. Lipoatrophy associated with daily growth hormone injections
The practical lesson is straightforward: rotate your injection sites. Moving the injection to a different spot each day prevents the hormone from concentrating in one area long enough to dissolve the local fat. Most prescribing information for HGH already emphasizes site rotation, and following that guidance greatly reduces the risk.
When Subcutaneous Injections Accidentally Go Intramuscular
Even people who intend to inject subcutaneously sometimes end up injecting into muscle, especially at certain body sites. Research on insulin injection depth found that the thigh has particularly thin subcutaneous tissue in many people. When an 8 mm needle was inserted at a 90-degree angle without pinching the skin, the estimated risk of reaching muscle was about 25% at the thigh and roughly 10% at the abdomen. Switching to a shorter 4 mm needle dropped those risks dramatically.12PubMed. Intramuscular risk at insulin injection sites–measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy
While that study was conducted with insulin rather than growth hormone, the anatomy is the same. If you are injecting HGH into the thigh with a longer needle, there is a real chance you are delivering it intramuscularly without realizing it. For growth hormone, this accidental intramuscular delivery is less dangerous than it is for insulin, since the clinical outcomes of the two routes are so similar. You would not experience the kind of sudden hypoglycemia that a diabetic patient might face from accidentally intramuscular insulin. But it does mean your absorption profile will look more like the sharp-spike pattern rather than the slow-release one, and over time that inconsistency could make your response to therapy less predictable.
The simplest way to reduce this risk is to use a shorter needle and pinch a fold of skin before injecting. Most modern HGH pen devices come with needles short enough to make accidental intramuscular penetration unlikely, but if you are using syringes and drawing from vials, needle length is something worth discussing with your prescriber.
Drug Wastage and Delivery Devices
Because HGH is an expensive medication, the efficiency of the delivery device matters financially. Modern pen injectors vary in how much hormone they waste per cartridge. A laboratory simulation comparing two common devices found that one wasted about 5.5 mg of growth hormone per patient per year, while the other wasted roughly 43.6 mg, a difference that translated to seven or eight additional pens per patient annually.13PubMed Central. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis All of these pen devices are designed for subcutaneous injection. No commercially available HGH auto-injector is designed for intramuscular use, which means anyone choosing the intramuscular route would need to draw the hormone into a separate syringe, a process that typically wastes more medication than a pen device does.
This is a hidden cost of intramuscular injection that rarely gets discussed. Even if you have a clinical reason to prefer the intramuscular route, you will likely use more product per treatment cycle simply because the delivery method is less efficient.
HGH Abuse in Sports and Unsupervised Use
Outside of prescribed medical therapy, growth hormone is widely used in athletic and bodybuilding contexts for its anabolic and fat-burning properties. Athletes who self-administer HGH are often doing so without medical supervision and may use either injection route depending on personal preference or advice from other users rather than clinical evidence.14PubMed Central. Growth hormone, IGF-I and insulin and their abuse in sport
In these unsupervised settings, the risks of intramuscular injection are amplified. Without proper training, users may inject into the wrong muscle group, use an inappropriate needle length, or reuse needles. The doses used for performance enhancement are often much larger than therapeutic doses for deficiency, and combining HGH with insulin and IGF-I, as some athletes do, adds layers of risk that dwarf the injection-route question entirely. If you are using growth hormone outside of medical supervision, the route of injection is far from your biggest safety concern, but the nerve-injury and hematoma risks described earlier are real and avoidable by sticking with subcutaneous injection.
Handling and Storage Considerations
Growth hormone is a protein, and like most proteins, it can aggregate and lose potency if handled roughly. Laboratory testing has shown that the primary driver of HGH aggregation is exposure to a dynamically renewed air-liquid interface, essentially, repeated shaking that creates and disrupts bubbles at the surface. When the hormone solution was kept still or filled high enough to eliminate that air-liquid boundary, it remained stable.1Pediatric Research. Absorption of human growth hormone injected subcutaneously and intramuscularly in growth deficient dwarfs
This applies equally to both injection routes, but it is especially relevant for anyone who reconstitutes lyophilized (freeze-dried) HGH at home. The standard advice to swirl gently rather than shake the vial exists for good reason: aggressive mixing can degrade the hormone before it ever enters your body. Reconstituted growth hormone should be refrigerated and used within the timeframe specified by the manufacturer, typically within a few weeks. Letting it sit at room temperature or shaking the vial accelerates protein breakdown and can reduce the effective dose you receive with each injection.
None of this changes whether you inject subcutaneously or intramuscularly, but it underscores a broader point about HGH therapy: the route of injection is only one variable among many that determine whether you get the full benefit of each dose. Proper storage, gentle handling, consistent timing, and site rotation all matter at least as much as whether the needle reaches fat or muscle.